1-877-755-8324

News / Blogs

 

2017

    In a recent study with Alzheimer's disease animal model (APP/PS1 double transgenic mice), Anogen anti- amyloid peptide N-terminus antibody clone 3F5 reduced plaque on brain and improved cognition.

2016

    More than 50 new hybridomas were developed. These hybridomas secrete monoclonal antibodies against important therapeutic targets suct as PD-1, PDL-1 and IL-17A. The monoclonal antibodies are under evaluation. An assay that measures PDL-1 concentration in blood samples has been developed.

 

     Developed antibodies against primary tumor cells of triple negative breast cancer.

2015

    Participated in the laboratory medicine and pathology (LMP) vendor show in University of Toronto. 

 

     Developed amyloid beta 42 peptide ELISA kit.  Completed evaluation of anti-amyloid peptide antibodies with transgenic Alzheimer's disease mouse model.  

2014

    Launched an upgraded website: www.anogen.net

2013

    Line of Mouse ELISA Kits released.

2012



 

    Started developing animal cytokine and chemokine products. New ELISA Kit products for mouse cytokine and receptors have been released.

    Set up a Facebook page and storefront.

    Released new Interleukin-6 (IL-6) anti-human antibodies and Tau Protein (Thr181 Phosphorylated) anti-human and mouse antibodies. They can be found in our monoclonal antibody listings.

2011





    Alpha 1-Antitrypsin and Alpha-Synuclein anti-human antibodies released.

    Interleukin-13 (IL-13) ELISA kit released.

    Beta amyloid peptide N-terminal and 40 anti-human antibodies released.

    Multiplex ELISA kit for simultaneous quantitative determination of pro-inflammatory cytokines released.

    Started preparing a new facility in Orlando, FL, USA.

2010



    Monoclonal antibodies for Interleukin-2, H.pylori(HP) cytotokine associated gene A protein (CagA) and M. tuberculosis (TB) 38Kd antigen released.

    “Humanized monoclonal antibody against the chemokine CXCL-8 (IL-8) effectively prevents acute lung injury” published in International Immunopharmacology.

2009


    Received Certificate of Recognition from the City of Mississauga on Anogen's 20th Anniversary.

    Developed panels of monoclonal antibodies to Alzheimer’s disease.

2008

 

    Introduced Beta-2 Microglobulin matched antibody pair, Beta-2 Microglobulin and p24 ELISA kits.

    Polyclonal antibodies for FPRL-1 and PML and a line of new phosphorylated monoclonal antibodies for CREB [p-S133], ELK-1 [pS383], and STAT5b [p-T694] released.

2007


    New lung carcinoma, free PSA, CEA, AFP, NSE and CA-125 antibodies released.

    Free PSA and AFP ELISA kits released.

2006


    Anogen introduced our new line of ELISPot kits.

    US patent “Topical Treatment Of Psoriasis Using Neutralizing Antibodies To Interleukin-8” granted.

2005

    US patent “Monoclonal Antibodies Recognizing Human Platelet Membrane Glycoproteins And Use Thereof In Anti-Thrombotic Therapy” granted.

2004

    Anti-human platelet GPIIb/IIIa chimeric antibody completed pre-clinical studies.

2003


    Certified ISO 13485:03 Medical Devices under the general practice of the ISO 9001 Quality System.

    Humanized monoclonal antibodies to human platelet GPIIb/IIIa, to human IL-8 and to human MCP-1 developed for therapeutics.

2002

    Anti-IL8 neutralizing antibody cream (Abcream), developed for topical treatment of psoriasis and eczema, completed clinical trials in China.

2001

    Received patents from Australia, Canadian, China, and EU for "Topical Treatment Of Psoriasis Using Neutralizing Antibodies To Interleukin-8".

1998

    Developed a proprietary technology for topical antibody treatment of various skin conditions, representing a new area of antibody therapy.

1993


    Monoclonal antibodies to human serum amyloid A (SAA) and SAA ELISA Kit developed.

    Development of revolutionary anti-chemokine topical therapy for skin conditions started.

1992

 

    Developed panels of monoclonal antibodies to Chemokines MCP-1 and MCP-3 and ELISA Kits.

    Received grant from National Research Council (NRC) Canada Biotechnology Contribution Program on the “Development Of A Specific & Sensitive Assay For Blood-Borne Non-A, Non-B Hepatitis Virus”.

1991

    Developed panel of monoclonal antibodies to Chemokines Interleukin-8 (IL-8) and IL-8 ELISA kit.

1990

    Developed panels of monoclonal antibodies to Hepatitis C and HIV viruses.

1989

    Anogen-Yes Biotech Laboratories Ltd. was registered at Mississauga, Ontario, Canada.